The American Urological Association Symptom Index for Benign Prostatic Hyperplasia

Barry, Michael J.; Fowler, Floyd J.; O’Leary, Michael P.; Bruskewitz, Reginald C.; Holtgrewe, H. Logan; Mebust, Winston K.; Cockett, Abraham T.K.

doi:10.1016/s0022-5347(17)36966-5

Cited by 2,997 publications

(1,373 citation statements)

References 12 publications

Supporting

Mentioning

1,331

Contrasting

Unclassified

Order By: Relevance

“…13 It is stated that the degree to which urinary dif®culties bother the BPH patient and affects his daily activities varies considerably among individual patients reporting the same symptoms. 14 So the Third International WHO Conference on BPH 15 and the AHCPR guidelines 11 recommended assessing Quality of Life in BPH patients with validated tools complementary to symptom frequency (IPSS) 16 and degree of bothersomeness (BPH Impact Index) 17 measurements.…”

Section: Introductionmentioning

confidence: 99%

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

Lukacs

Grange

Comet

et al. 1998

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Objectives: To investigate (a) the magnitude and durability of symptom score reduction and HRQL score improvement (including sexual drive); (b) adverse outcomes; and (c) progression to acute urinary retention and prostate surgery up to three years of treatment with alfuzosin.Methods: Three thousand two hundred and twenty-eight BPH-patients out of 812 centers were included in a prospective three-year open-labelled study and treated with alfuzosin (immediate release formulation) at the recommended dosage. A symptom score (Boyarsky modi®ed) and a 20-item BPH speci®c HRQL score including three questions of sexuality (Urolife TM BPH QoL 20) were selfadministered at baseline, 3,6,12,18,24,30, and 36 months.Results: Two thousand ®ve hundred and seventy-nine patients (79.9%) completed the study at the end of three years. Symptom score was signi®cantly reduced by 54% at 3 months and this reduction was maintained up to 36 months (748.4%); HRQL score was signi®cantly improved by 45.4% at 12 months and this improvement was maintained up to 36 months ( 43.4%). Alfuzosin was well tolerated: the quantitative and qualitative distribution of adverse events was similar to that previously observed in placebo-controlled studies (vertigo/dizziness: 2.1%). Adverse events accounted for 4.2% of the drop-outs. 120 patients (3.7%) were operated on for BPH and nine patients (0.3%) experienced acute urinary retention.Conclusion: This medical outcomes study con®rms the long-term safety pro®le of alfuzosin in the naturalistic conditions of general practice and highlights the need to measure HRQL in the context of patient's preferences.

show abstract

Section: Introductionmentioning

confidence: 99%

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

Lukacs

Grange

Comet

et al. 1998

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…Lastly, we included the IPSS primarily as a control since it is well known, reproducible standard self-assessment of male LUTS [Barry et al, 1992]. Because the IPSS is not incontinence-speci¢c we also broke it into subscores by summing the scores for the storage and voiding symptom-speci¢c questions.…”

Section: Discussionmentioning

confidence: 99%

“…We also included an evaluation of the International Prostate Symptom Score (IPSS) derived from the American Urological Association symptom score as a control, since it is a widely utilized, reliable standard of self-assessment for male lower urinary tract symptoms [Barry et al, 1992]. The IPSS also allows for the assessment of symptoms other than incontinence.…”

Section: Introductionmentioning

confidence: 99%

Comparison between reduction in 24‐hour pad weight, International Consultation on Incontinence‐Short Form (ICIQ‐SF) score, International Prostate Symptom Score (IPSS), and Post‐Operative Patient Global Impression of Improvement (PGI‐I) score in patient evaluation after male perineal sling

Twiss

Fischer

Νitti

2006

Neurourology and Urodynamics

View full text Add to dashboard Cite

Aims:We assessed the utility of three self-assessment instruments: the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), the post-operative Patient Global Impression of Improvement (PGI-I) score, and the International Prostate Symptom Score (IPSS) by correlating them with an objective outcome, the change in 24-hr pad weight, after a male perineal sling. Methods: Twenty-six men with urodynamically con¢rmed stress incontinence underwent a male perineal sling. Patients were evaluated pre-operatively and post-operatively with a 24-hr pad test, IPSS and ICIQ-SF. Patients also completed the PGI-I post-operatively. Changes in study parameters were compared via the paired t-test, and correlations were performed using Spearman's rho. Results: There were signi¢cant reductions in 24-hr pad weight (À274 g, P < 0.001), percentage 24-hr pad weight (54.2%), ICIQ-SF score (À6.3, P < 0.001), and the three ICIQ-SF subscores (À1.2, À1.7, À3.4 for Questions 3, 4, and 5, respectively, P < 0.001 for all). The change in total ICIQ-SF score and the post-operative PGI-I score correlated strongly with percentage reduction in 24-hr pad weight (r ¼ À0.68, P < 0.001; r ¼ À0.81, P < 0.001, respectively) and with each other (r ¼ 0.79, P < 0.001). The change in all three ICIQ-SF subscores correlated signi¢cantly with percentage reduction in 24-hr pad weight and with post-operative PGI-I score. There was no signi¢cant change in the IPSS or the voiding or storage subscores, and none correlated with any other study parameter. Conclusions: This study validates the construct validity of the ICIQ-SF and PGI-I in the assessment of treatment for male stress incontinence and should make clinicians con¢dent in comparing studies of incontinence treatment utilizing the change ICIQ-SF score, the post-operative PGI-I score, and percentage reduction in 24-hr pad weight as outcome measures.

show abstract

“…To evaluate amount of comprehensive bothersomeness of urinary function, we used the International Prostate Symptom Score quality of life (I-PSS QOL) score. 11 We also used other questions related to stress incontinence and number of pads use (Appendix A). The questionnaire consisted of two questions, as follows: (1) does coughing and/or sneezing induce leakage of urine?…”

Section: Qol Methodsologymentioning

confidence: 99%

A 3-y prospective study of health-related and disease-specific quality of life in patients with nonmetastatic prostate cancer treated with radical prostatectomy or external beam radiotherapy

Yoshimura

Arai

Ichioka

et al. 2004

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

We assessed the longitudinal alteration of the quality of life (QOL) of patients with localized prostate cancer after radical prostatectomy or hormonoradiotherapy during 3-y follow-up. In addition, we examined the impact on QOL of initiation of second treatment after failure of primary treatment. In all, 135 patients with localized prostate cancer who underwent radical retropubic prostatectomy (RP) (N ¼ 84) or external beam radiotherapy with neoadjuvant hormone (XRT) (N ¼ 51) at our institute and who had a minimum follow-up of 3 y were included in this study. Data were collected prospectively, at baseline, at 3 months after treatment, at 1 y, and annually thereafter. QOL, generic and disease-targeted was evaluated using the European Organization for Research and Treatment of Cancer Prostate Cancer QOL Questionnaire, the Sapporo Medical University Sexual Function Questionnaire, the International Prostate Symptom Index Quality of Life Score and similar questions regarding bowel function. Repeated-measures ANOVA revealed significantly different patterns of alteration in the domains of QOL, with the exception of several domains, between the RP and XRT groups. Rapid decline of sexual function and increase in sexual bothersomeness were followed by slight amelioration throughout follow-up in the RP group, and did not change thereafter in the XRT group. Overall satisfaction with urinary condition significantly improved after treatment and that with bowel condition was stable during followup in both of the groups. Failure of primary treatment and initiation of salvage treatment had no impact on QOL. This prospective study revealed longitudinal alteration of QOL status of patients undergoing treatment for localized prostate cancer, but did not yield any conclusions regarding effect of treatment failure and second treatment on QOL due to small sample size. It should be noted that different instruments for assessment of QOL can generate different outcomes.

show abstract

The American Urological Association Symptom Index for Benign Prostatic Hyperplasia

Cited by 2,997 publications

References 12 publications

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

Comparison between reduction in 24‐hour pad weight, International Consultation on Incontinence‐Short Form (ICIQ‐SF) score, International Prostate Symptom Score (IPSS), and Post‐Operative Patient Global Impression of Improvement (PGI‐I) score in patient evaluation after male perineal sling

A 3-y prospective study of health-related and disease-specific quality of life in patients with nonmetastatic prostate cancer treated with radical prostatectomy or external beam radiotherapy

Contact Info

Product

Resources

About